Jubilant Pharmova Limited has informed the Exchange that Board of Directors at its meeting held on May 22, 2026, recommended Final Dividend of Rs. 5 per equity share.
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jubilant Pharmova's Board approved audited FY2026 consolidated results showing revenue from operations grew 14.4% to Rs 82,250 million from Rs 71,921 million. However, profit after tax (PAT) declined significantly by 41.5% to Rs 5,393 million from Rs 9,213 million in the previous year. The Board recommended a final dividend of Rs 5 per equity share (500%) for FY2026, subject to shareholder approval. Exceptional items during the year included a gain of Rs 236 million from sale of held-for-sale assets, Rs 535 million in expenses for remediation at a Canadian manufacturing facility, and Rs 133 million related to new labour code implementation. Statutory auditors Walker Chandiok & Co LLP issued unmodified (clean) opinions on both standalone and consolidated financial statements.
The 41.5% PAT decline despite revenue growth signals margin pressure, likely due to exceptional items and operational challenges at certain facilities. The dividend commitment indicates management confidence, but investors should watch for impact on cash flows and the remediation costs at the Canadian facility.